- Rank in Search Criteria: 3351
World Rank (Jan-05-2024): 6,697
Market Cap (Jan-05-2024): 1.53 Billion USD
World Rank (Jul-30-2023): 4890
Market Cap (Jul-30-2023): 2.53 Billion USD
World Rank (Jan-2022): 7,957
Market Cap (Jan-2022): 1.34 Billion USDHeadquarters Country: China
- Rank in Search Criteria: 3352
World Rank (Jan-05-2024): 6,699
Market Cap (Jan-05-2024): 1.53 Billion USD
World Rank (Jul-30-2023): 5784
Market Cap (Jul-30-2023): 1.98 Billion USD
World Rank (Jan-2022): 5,008
Market Cap (Jan-2022): 2.87 Billion USDHeadquarters Country: China
- Rank in Search Criteria: 3353
World Rank (Jan-05-2024): 6,702
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 6265
Market Cap (Jul-30-2023): 1.74 Billion USD
World Rank (Jan-2022): 5,459
Market Cap (Jan-2022): 2.52 Billion USDHeadquarters Country: China Annual Revenue in USD: 1,271 Million USD
Annual Net Income in USD: 171 Million USD
Annual Results for Period ending: Dec-2021 ending year
- Rank in Search Criteria: 3354
World Rank (Jan-05-2024): 6,704
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 11580
Market Cap (Jul-30-2023): 0.60 Billion USD
World Rank (Jan-2022): 18,364
Market Cap (Jan-2022): 0.23 Billion USDHeadquarters Country: India
- Rank in Search Criteria: 3355
World Rank (Jan-05-2024): 6,705
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 6434
Market Cap (Jul-30-2023): 1.66 Billion USD
World Rank (Jan-2022): 5,117
Market Cap (Jan-2022): 2.78 Billion USDHeadquarters Country: China Annual Revenue in USD: 3,155 Million USD
Annual Net Income in USD: 397 Million USD
Annual Results for Period ending: Dec-2021 ending year
- Rank in Search Criteria: 3356
World Rank (Jan-05-2024): 6,706
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 8045
Market Cap (Jul-30-2023): 1.15 Billion USD
World Rank (Jan-2022): 11,201
Market Cap (Jan-2022): 0.73 Billion USDAnnual Revenue in USD: 346 Million USD
Annual Net Income in USD: 55 Million USD
Annual Results for Period ending: Dec-2021 ending year
- Rank in Search Criteria: 3357
World Rank (Jan-05-2024): 6,709
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 6610
Market Cap (Jul-30-2023): 1.60 Billion USD
World Rank (Jan-2022): 4,277
Market Cap (Jan-2022): 3.58 Billion USDHeadquarters Country: China Annual Revenue in USD: 493 Million USD
Annual Net Income in USD: 34 Million USD
Annual Results for Period ending: Dec-2021 ending yearEmployee Count: 5,357
Employee Count as of Date: As on 2020
- Rank in Search Criteria: 3358
World Rank (Jan-05-2024): 6,710
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 7521
Market Cap (Jul-30-2023): 1.28 Billion USD
World Rank (Jan-2022): 7,843
Market Cap (Jan-2022): 1.37 Billion USDHeadquarters Country: India Annual Revenue in USD: 166 Million USD
Annual Net Income in USD: 51 Million USD
Annual Results for Period ending: Mar-2022 ending yearEmployee Count: 4,044
Employee Count as of Date: As on March 2020, it has 2,239 Permanent Employees and remaining are Contractual Employees
Company Profile: Eris Lifesciences is a pharmaceutical company with a generation of actionable medical evidence through initiatives such as the India Heart Study (IHS) and India Diabetes Study (IDS). The company annual revenue is 13,470 million INR and annual net income is 4,061 million INR for year ending March 2021. The headquarters is in India.
- Rank in Search Criteria: 3359
World Rank (Jan-05-2024): 6,714
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 5244
Market Cap (Jul-30-2023): 2.30 Billion USD
World Rank (Jan-2022): 3,503
Market Cap (Jan-2022): 4.60 Billion USDHeadquarters Country: China Annual Revenue in USD: 298 Million USD
Annual Net Income in USD: 105 Million USD
Annual Results for Period ending: Dec-2021 ending yearEmployee Count: 2,007
Employee Count as of Date: As on 2020
- Rank in Search Criteria: 3360
World Rank (Jan-05-2024): 6,715
Market Cap (Jan-05-2024): 1.52 Billion USD
World Rank (Jul-30-2023): 5684
Market Cap (Jul-30-2023): 2.03 Billion USD
World Rank (Jan-2022): 2,240
Market Cap (Jan-2022): 8.02 Billion USDHeadquarters Country: China Annual Revenue in USD: 675 Million USD
Annual Net Income in USD: 300 Million USD
Annual Results for Period ending: Dec-2021 ending yearCompany Profile: CanSino Biologics is an Innovative Biopharmaceutical company. It is currently developing 16 vaccine candidates for 13 infectious disease areas, preventing meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. The headquarters is in China.